Identifying early events of gene expression in breast cancer with systems biology phylogenetics

Cytogenetic and Genome Research

Volumn 139, Issue 3, 2013, Pages 206-214

  Abu Asab, M S ^a   Abu Asab, N ^d   Loffredo, C A ^b   Clarke, R ^b   Amri, H ^c  

^a NATIONAL EYE INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

Cancer; Early events; Heterogeneity; Parsimony; Phylogenetics; Synapomorphies; Systems biology

Indexed keywords

TUMOR MARKER;

ARTICLE; AUTISM; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER TISSUE; CARCINOGENESIS; CLONAL ABERRATION; EPIGENETICS; GENE EXPRESSION; GENE SEQUENCE; GENETIC PARAMETERS; GENOMICS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METABOLOMICS; NEOPLASM; NONCLONAL ABERRATION; PHYLOGENY; PRIORITY JOURNAL; PROTEOMICS; RETINA MACULA DEGENERATION; SPECTRAL KARYOTYPING; VALIDATION PROCESS; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN TISSUE;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYLOGENY; REFERENCE VALUES; SYSTEMS BIOLOGY;

EID: 84875653990     PISSN: 14248581     EISSN: 1424859X     Source Type: Journal    
DOI: 10.1159/000348433     Document Type: Article

References (31)

1. Abu-Asab MS, Chaouchi M, Amri H: Phyloproteomics: What phylogenetic analysis reveals about serum proteomics. J Proteome Res 5: 2236-2240 (2006). (Pubitemid 44330816)
2. Abu-Asab MS, Chaouchi M, Amri H: Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics Clin Appl 2: 122-134 (2008a). (Pubitemid 351284894)
3. Abu-Asab MS, Chaouchi M, Amri H: Phylogenetic modeling of heterogeneous gene-expression microarray data from cancerous specimens. Omics 12: 183-199 (2008b).
4. Abu-Asab MS, Chaouchi M, Alesci S, Galli S, Laassri M, et al: Biomarkers in the age of omics: Time for a systems biology approach. Omics 15: 105-112 (2011).
5. Berman JJ: Precancer: The Beginning and the End of Cancer. (Jones and Bartlett Publishers, Sudbury 2010).
6. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, et al: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107: 18545-18550 (2010).
7. Buchen L: Cancer: Missing the mark. Nature 471: 428-432 (2011).
8. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, et al: Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat 119: 335-346 (2010).
9. Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, et al: The properties of high-dimensional data spaces: Implications for exploring gene and protein expression data. Nat Rev Cancer 8: 37-49 (2008).
10. Couzin-Frankel J: Personalized medicine. Pushing the envelope in neuroblastoma therapy. Science 333: 1569-1571 (2011).
11. Daley GQ: Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb Symp Quant Biol 73: 171-174 (2008).
12. Diamandis EP: Cancer biomarkers: Can we turn recent failures into success? J Natl Cancer Inst 102: 1462-1467 (2010).
13. Felsenstein J: PHYLIP: Phylogeny Inference Package (Version 3.2). Cladistics 5: 164-166 (1989).
14. Fendt L, Niederstätter H, Huber G, Zelger B, Dünser M, et al: Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection. Breast Cancer Res Treat 128: 327-336 (2011).
15. Ganeshan B, Strukowska O, Skogen K, Young R, Chatwin C, Miles K: Heterogeneity of focal breast lesions and surrounding tissue assessed by mammographic texture analysis: Preliminary evidence of an association with tumor invasion and estrogen receptor status. Front Oncol 1: 33 (2011).
16. Goldstein DB, Need AC, Singh R, Sisodiya SM: Potential genetic causes of heterogeneity of treatment effects. Am J Med 120:S21-25 (2007). (Pubitemid 46497040)
17. Graham K, de las Morenas A, Tripathi A, King C, Kavanah M, et al: Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer 102: 1284-1293 (2010).
18. Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ: Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J Cell Physiol 220: 538-547 (2009).
19. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ: Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr Drug Targets 11: 1304-1316 (2010).
20. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, et al: Decoding the genome beyond sequencing: The new phase of genomic research. Genomics 98: 242-252 (2011a).
21. Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ: Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 112: 217-253 (2011b).
22. Heppner GH, Miller BE: Tumor heterogeneity: Biological implications and therapeutic consequences. Cancer Metastasis Rev 2: 5-23 (1983).
23. Koturbash I, Beland FA, Pogribny IP: Role of epigenetic events in chemical carcinogenesis-a justification for incorporating epigenetic evaluations in cancer risk assessment. Toxicol Mech Methods 21: 289-297 (2011).
24. Landen CN Jr, Birrer MJ, Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005 (2008). (Pubitemid 351398093)
25. Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: Clinical implications. Cancer Res 68: 3551-3557 (2008).
26. Lyons-Weiler J, Patel S, Becich MJ, Godfrey TE: Tests for finding complex patterns of differential expression in cancers: Towards individualized medicine. BMC Bioinformatics 5: 110 (2004).
27. Michor F, Polyak K: The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) 3: 1361-1364 (2010).
28. Pogribny IP: Epigenetic events in tumorigenesis: Putting the pieces together. Exp Oncol 32: 132-136 (2010).
29. Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, et al: P53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 4: 223-231 (1995).
30. Sumer B, Gao J: Theranostic nanomedicine for cancer. Nanomedicine (Lond) 3: 137-140 (2008). (Pubitemid 351611851)
31. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, et al: Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer 122: 1557-1566 (2008). (Pubitemid 351294964)